Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

NCT02339532 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: FEC100
DRUG: Docetaxel
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Carboplatin

Sponsor

UNICANCER